CASE CCC IN THE NEWS
CWRU School of Medicine Researchers Discover New Target for Personalized Cancer T2herapy
E Science News - May 5, 2013
A common cancer pathway causing tumor growth is now being targeted by a number of new cancer drugs and shows promising results...By disrupting the mutated signaling pathway, the Case Western Reserve team, led by John Wang, PhD, inhibited the growth of cancer cells, opening the possibility to new cancer therapies..."This research will impact the field by focusing us on new targets for treating and preventing metastasis in patients in a many different types of human cancers," said Stanton Gerson, MD.
FDA Panel Votes Down Two Cancer Drugs
MedPage Today - May 2, 2013
"I cannot picture how I would be able to talk with a patient about treating him or her with a drug, tivozanib, that would allow that person to live without progression longer but to possibly die faster than if I treated that person with another available renal cell carcinoma drug," committee Chair Mikkael Sekeres, MD, MS, of the Cleveland Clinic's Taussig Cancer Institute, said.
Increased Exposure Likely Driving 'Epidemic' of HPV-associated Cancers
Helio/HemOnc Today - Apr 25, 2013
"The expectation is that the vaccines will prevent oropharyngeal cancers in future, but we are not there yet,"David Adelstein, MD, a staff physician in the department of solid tumor oncology at Cleveland Clinic's Taussig Cancer Institute, told HemOnc Today.
Clues to Cancer
For the past week, the Plain Dealer has been running Clues to Cancer, a series of stories about Phase I clinical trials at Seidman Cancer Center and the Case Comprehensive Cancer Center. The articles attempt to show various aspects of clinical trials, from patients and their families, to the doctors and nurses who treat the patients, and the researchers searching for a cure.
Clues to Cancer: Plain Dealer series follows patients as they join doctors on road to discovery
Vince Petro gets some encouraging news, keeps his focus forward
Scared but resolute, Vince Petro enters the unknown of Phase 1 clinical trial
Nurses study patients' critical connections during Phase 1 clinical trials
Side effects of drugs push Margene Manning to the limit
Margene Manning must decide if signing on for Phase 1 clinical trials is worth sacrifice
The road to enrollment in Phase 1 clinical trials is a long one
Who pays for drugs used in Phase 1 clinical trials?
Keeping clinical trials on track is a challenge to doctors, nurses
A weakening Carl Gehringer Jr. can't continue with new treatments
New trials give 2 lymphoma and leukemia patients will to keep fighting
Centers put high value on doing their own research
20 years of collaboration and lab work precede testing in humans
Larry Tremaglio and Georgine Riley consider trials, say, 'Why not?'
Minority patient participation crucial to Phase 1 clinical trials
Despite a losing battle, John Soley hopes his case helps others
Janet Whitney was open to all options for treatment
For Barbara Malone and other patients, success often comes in modest steps
2-way street of inspiration in a grandmother and her family
What is learned during clinical trials and how patients benefit
MARK YOUR CALENDARS
2013 Theodore J. Castele, MD Lecure
The Department of Radiology will present the 21st Annual Theodore J. Castele, MD Lecure on Tuesday, May 21 in the Wolstein Research Building Auditorium. Guest speaker Sanjiv Sam Gambhir, MD, the Virginia & DK Ludwig Professor of Cancer Research and Chair of Radiology at Stanford University, will present, Novel Strategies for the Earlier Detection of Cancer. The evening will start with award presentations at 5 pm followed by the lecture at 5:30 pm. Please RSVP to marianne.chaloupek@UHhospitals.org by May 13.
Race for the Place- Join Our Team!
The Race for the Place, an event that benefits the Gathering Place, will be held Sunday, June 2 at Beachwood Place Mall. The Case CCC has created a team. Click here to join the team or to show your support by making a donation. Contact Gillian Todd for more information.
Impact of Genomics on Cancer Diagnosis and Treatment: Open Drug Policy Forum
The Case CCC, in partnership with five other Midwest comprehensive cancer centers, will convene a public forum on the emerging revolution in genetic testing known as precision or personalized medicine on Monday, June 10. Experts from the government, pharmaceutical and insurance industries, public health sector, and the cancer research community will participate in dynamic lectures and discussions to consider the complexities of integrating genetic testing into cancer care.
This forum is free and open to the public. Pre-registration is required: http://goo.gl/xEuwA.
Planned discussions include:
Keynote Address: How Genomics May Transform Cancer Care
Arul Chinnaiyan, MD, PhD
How to Validate Genomic Based Decision Making in Cancer
Moderator: Sanford Markowitz, MD, PhD
Panel Members: Carl Morrison, DVM, MD; Robert J. Penny, MD, PhD; Michael A. Tainsky, PhD
Implications for Public Policy-Discussion with Congressional Representatives and NCI/FDA
Moderator: Donald L. Trump, MD
Panel Members: James H. Doroshow, MD; Stanton L. Gerson, MD; Elizabeth A. Mansfield, PhD; Anthony Murgo, MD, MS; Richard Schilsky, MD
Challenges for the FDA and CMS: Drug Approval and Reimbursement for Off-label Drug Use for Cancer Genetic Alteration
Moderator: Richard Schilsky, MD
Panel Members: James H. Doroshow, MD; Martine George, MD, MSc; Elizabeth A. Mansfield, PhD; Neal Meropol, MD; Anthony Murgo, MD, MS
Genomics and Drug Reimbursement: White Paper from the Cleveland Forum 2013
Moderator: Stanton L. Gerson, MD
Panel Members: Brian Bolwell, MD; Richard Schilsky, MD; Donald L. Trump, MD; Max S. Wicha, MD
Implementing Proper Use of Genomic Tests to Select Therapeutics
Moderator: Lyndsay Harris, MD
Panel Members: James H. Doroshow, MD, Candace S. Johnson, PhD; Patricia M. LoRusso, DO
More information is on the Cancer Center site.
Annual Scientific Retreat
The Annual Cancer Center Scientific Retreat will commence the evening of Thursday, July 11 with a speaker and reception in the Wolstein Research Building Auditorium. The Retreat will continue the next day, Friday, July 12, at Corporate College East. The agenda is still be finalized. Details will be circulated soon!
Ovarian Cancer Research Program
Applications to the Fiscal Year 2013 (FY13) Ovarian Cancer Research Program (OCRP) are being solicited for the Assistant Secretary of Defense for Health Affairs, Defense Health Program, by the U.S. Army Medical Research Acquisitions Activity:
- The overarching goal of the Ovarian Cancer Academy is to develop successful, highly productive ovarian cancer researchers in a collaborative research training environment. The Ovarian Cancer Academy Award - Early-Career Investigator is soliciting additional Early-Career Investigators to join the existing Academy.
- The OCRP Pilot Award supports conceptually innovative, high-risk/high-reward research that could ultimately lead to critical discoveries or major advancements that will drive the field of ovarian cancer research forward. The proposed research should include a testable hypothesis based on strong scientific rationale and serve as a catalyst to expand or modify current thinking about and/or approaches in ovarian cancer research.
- The OCRP Teal Innovator Award supports a visionary individual from any field principally outside of, but not exclusive of, ovarian cancer to focus his/her creativity, innovation, and leadership on ovarian cancer research.
Pre-Application Deadline: June 12
Application Deadline: August 28
Dr. Andrew Sloan Receives Award for
Last month, Dr. Andrew Sloan received the Mahaley Award for Clinical Research in Neuro-Oncology by the National Brain Tumor Foundation at the 81st Annual Meeting of the American Association of Neurological Surgeons for his work targeting glioma stem cells. Dr. Sloan gave a presentation,Targeting Glioma Stem Cells in GBM: A Phase O/II study of Hedgehog Pathway inhibitor GDC-0449, on which he collaborated with Drs. Charles Nock, Amber Kerstetter,John Pink, Jeremy Rich, MD, Naoko Takebe, Robert Miller, Michael Prados, and Stuart Grossman.
BME Student Wins Second Place at Imaging Conference
Asha Singanamalli, a second year student in Biomedical Engineering mentored by Dr. Anant Madabhushi, was runner-up for best student paper at SPIE Medical Imaging 2013. She beat out 40 other student papers and seven other finalists to receive second place for her paper, Identifying in Vivo Dce MRI parameters correlated with ex Vivo quantitative microvessel characteristics: a radiohistomorphometric approach. The paper introduces a framework called radiohistomorphometry that allows for identification of novel DCE MRI biomarkers for distinguishing prostate cancer patients who need aggressive treatment from those who may be more suited for active surveillance.